ABCC2 inhib 
Welcome,         Profile    Billing    Logout  
 0 Companies   0 Products   0 Diseases   0 Trials   0 News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BT051 / Bacainn Therap
SCOUT, NCT05084261: An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

Recruiting
1
44
US, RoW
BT051 200 mg, BT051 800 mg, BT051 3200 mg, BT051 up to 3200 mg, Matching Placebo
Bacainn Therapeutics, Inc.
Ulcerative Colitis
08/23
08/23

Download Options